Abstract
Multidrug-resistant/extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa (PA) are critical antimicrobial resistance threats. Despite their increasing prevalence, treatment options for metallo-b-lactamase (MBL)-producing PA are limited, especially for New Delhi metallo-b-lactamase (NDM) producers. Pending further clinical studies, this case provides support for limited-scope use of cefepime-zidebactam for treating disseminated infections secondary to NDM-producing XDR PA. Susceptibilities should be tested and/or alternative regimens considered when treating isolates with alternative MBLs or increased efflux pump expression because some in vitro data suggest associated loss of cefepime-zidebactam susceptibility.
Original language | English (US) |
---|---|
Journal | Antimicrobial agents and chemotherapy |
Volume | 67 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2023 |
Keywords
- KEYWORDS Pseudomonas aeruginosa
- antimicrobial resistance
- cefepime-zidebactam
- extensively drug-resistant
- metallo-b-lactamase
- multidrug resistance
- novel antimicrobial agents
ASJC Scopus subject areas
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology